![Shengkan Jin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de Shengkan Jin
Sociétés | Poste | Début | Fin |
---|---|---|---|
Mito BioPharm LLC
![]() Mito BioPharm LLC Pharmaceuticals: MajorHealth Technology Mito BioPharm LLC is an American pharmaceutical company that focuses on developing therapies for non-alcoholic fatty liver disease (NAFLD), specifically non-alcoholic steatohepatitis (NASH) and type 2 diabetes. NAFLD is a range of conditions that start with fat accumulation in the liver and can progress to inflammation, fibrosis, cirrhosis, and even liver cancer. Mito BioPharm's drug discovery pipeline and intellectual property are aimed at addressing these conditions. | Directeur/Membre du Conseil | 01/01/2012 | - |
Directeur Technique/Scientifique/R&D | 01/01/2012 | - | |
Fondateur | 01/01/2012 | - |
Historique de carrière de Shengkan Jin
Statistiques
Internationale
Etats-Unis | 2 |
Opérationnelle
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Mito BioPharm LLC
![]() Mito BioPharm LLC Pharmaceuticals: MajorHealth Technology Mito BioPharm LLC is an American pharmaceutical company that focuses on developing therapies for non-alcoholic fatty liver disease (NAFLD), specifically non-alcoholic steatohepatitis (NASH) and type 2 diabetes. NAFLD is a range of conditions that start with fat accumulation in the liver and can progress to inflammation, fibrosis, cirrhosis, and even liver cancer. Mito BioPharm's drug discovery pipeline and intellectual property are aimed at addressing these conditions. | Health Technology |
- Bourse
- Insiders
- Shengkan Jin
- Expérience